What is Bridgebio?
BridgeBio Pharma, Inc. operates as a commercial-stage biopharmaceutical powerhouse dedicated to the discovery, development, and delivery of precision medicines. The company focuses on addressing the underlying causes of genetic diseases and cancers through a robust pipeline that includes next-generation oral small molecule stabilizers and advanced gene transfer technologies. By targeting specific molecular drivers of disease, Bridgebio aims to redefine the standard of care for patients suffering from conditions such as TTR amyloidosis, achondroplasia, and congenital adrenal hyperplasia. Its market position is defined by a rigorous, science-first approach to drug development, supported by a sophisticated capital structure that enables long-term commitment to complex therapeutic programs.
How much funding has Bridgebio raised?
Bridgebio has raised a total of $3B across 6 funding rounds:
Series C
$135M
Other Financing Round
$299.2M
Debt
$475M
Debt
$750M
Other Financing Round
$300M
Stock/Share Issuance
$1B
Series C (2017): $135M with participation from Perceptive Advisors, Cormorant Asset Management, and Aisling Capital
Other Financing Round (2019): $299.2M led by Hercules Capital, Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Steamboat Ventures
Debt (2020): $475M, investors not publicly disclosed
Debt (2021): $750M, investors not publicly disclosed
Other Financing Round (2025): $300M backed by HealthCare Royalty Management and Blue Owl
Stock/Share Issuance (2026): $1B with participation from HealthCare Royalty Management and Sixth Street
Key Investors in Bridgebio
Perceptive Advisors
A New York-based investment firm managing approximately $7 billion in assets, specializing in funding innovative healthcare and life sciences technologies.
Cormorant Asset Management
A prominent life sciences investment firm with over $3 billion in assets under management, focused on fundamental scientific principles to support innovative biotech companies.
Aisling Capital
A leading investment firm with over $1.8 billion in assets, dedicated to developing and commercializing transformative healthcare products and biopharmaceutical solutions.
What's next for Bridgebio?
Looking ahead, Bridgebio is poised to leverage its recent capital infusion to reach key clinical inflection points. The strategic focus remains on the successful execution of pivotal Phase 3 trials for its lead candidates, including AG10 and infigratinib, which are essential for securing regulatory approvals and subsequent commercial launches. Furthermore, the company is expected to continue its disciplined approach to resource allocation, potentially exploring further partnerships or non-dilutive financing arrangements to sustain its growth trajectory. As the firm matures, the integration of its gene therapy assets into the broader commercial framework will be a primary driver of long-term shareholder value and therapeutic impact.
See full Bridgebio company page
